Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Kivu Bioscience has raised $92.0M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
Kivu Bioscience's investors include Novo Holdings, HealthCap, BioGeneration Ventures, Red Tree Venture Capital, BOM.
Kivu Bioscience is headquartered in San Francisco, United States.
Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Kivu Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kivu Bioscience — Funding & Investors." VCBacked, October 28, 2024, https://www.vcbacked.co/company/kivu-bioscience. Accessed September 15, 2026.
VCBacked. (2024). Kivu Bioscience — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/kivu-bioscience
{{cite web |title=Kivu Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/kivu-bioscience |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated